search
Back to results

Multicenter Study Assessing the Efficacy & Safety of Hydroxychloroquine Sulfate in Patients With Systemic Lupus Erythematosus or Cutaneous Lupus Erythematosus With Active Lupus Erythematosus Specific Skin Lesion

Primary Purpose

Cutaneous Lupus Erythematosus-Systemic Lupus Erythematosus

Status
Completed
Phase
Phase 3
Locations
Japan
Study Type
Interventional
Intervention
hydroxychloroquine (Z0188)
Placebo
Sponsored by
Sanofi
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Cutaneous Lupus Erythematosus-Systemic Lupus Erythematosus

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion criteria :

  • Patients diagnosed as cutaneous lupus erythematosus (CLE)

Exclusion criteria:

  • Patients receiving corticosteroid more than 15mg/day of the equivalent dose of prednisolone.
  • Patients whose CLASI activity scores were less than 4 point at the initiation of Screening (Visit 1) and Day1 (Visit 2) (evaluated by a dermatology specialist).
  • Patients whose fluctuations of CLASI activity scores were ≥20% between Visit 1 and Visit 2 (evaluated by a dermatology specialist). The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Sites / Locations

  • Investigational Site Number 392017
  • Investigational Site Number 392022
  • Investigational Site Number 392011
  • Investigational Site Number 392003
  • Investigational Site Number 392001
  • Investigational Site Number 392008
  • Investigational Site Number 392009
  • Investigational Site Number 392005
  • Investigational Site Number 392014
  • Investigational Site Number 392019
  • Investigational Site Number 392007
  • Investigational Site Number 392020
  • Investigational Site Number 392012
  • Investigational Site Number 392010
  • Investigational Site Number 392013
  • Investigational Site Number 392006
  • Investigational Site Number 392018
  • Investigational Site Number 392002
  • Investigational Site Number 392023
  • Investigational Site Number 392021
  • Investigational Site Number 392004
  • Investigational Site Number 392016

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Other

Arm Label

HCQ

Placebo

Arm Description

HCQ 200~400mg, once daily, oral administration

HCQ-placebo, once daily, oral administration

Outcomes

Primary Outcome Measures

A change in CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index) activity score

Secondary Outcome Measures

A change in CLASI activity score
BILAG (British Isles Lupus Assessment Group) index to be conducted in patients complicated with SLE
RAPID 3 (Routine assessment of patient index data 3) to be conducted in patients complicated with SLE : daily life activity, pain associated with the original disease, patient's severity related to the original disease
QOL related to skin manifestations (skindex-29)
Dose reduction of concomitant corticosteroid
Global assessment by investigator (skin and other)
Global assessment by patient (skin)
Immunological parameters
Number of patients with serious adverse events / adverse events
Ophthalmologic examination (visual acuity examination, slit-lamp examination, funduscopic examination, visual field examination and color vision examination)

Full Information

First Posted
March 8, 2012
Last Updated
May 12, 2014
Sponsor
Sanofi
search

1. Study Identification

Unique Protocol Identification Number
NCT01551069
Brief Title
Multicenter Study Assessing the Efficacy & Safety of Hydroxychloroquine Sulfate in Patients With Systemic Lupus Erythematosus or Cutaneous Lupus Erythematosus With Active Lupus Erythematosus Specific Skin Lesion
Official Title
A Randomized, Double Blind, Baseline Controlled Study Using Placebo as Reference for Assessing the Efficacy and Safety of Hydroxychloroquine Sulfate in Patients With Systemic Lupus Erythematosus or Cutaneous Lupus Erythematosus in the Presence of Active Lupus Erythematosus Specific Skin Lesion
Study Type
Interventional

2. Study Status

Record Verification Date
May 2014
Overall Recruitment Status
Completed
Study Start Date
March 2012 (undefined)
Primary Completion Date
December 2013 (Actual)
Study Completion Date
April 2014 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Sanofi

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Primary Objective: - To investigate the efficacy on skin manifestation of 16 weeks treatment of once daily regimen of hydroxychloroquine sulphate (HCQ) in patients with cutaneous lupus erythematosus (CLE) and systemic lupus erythematosus (SLE) with active skin manifestation (CLASI [Cutaneous Lupus Erythematosus Disease Area and Severity Index] activity score is ≥4) concomitant treatment with or without corticosteroid. Secondary Objectives: To evaluate the efficacy on skin manifestation and the safety of 16 weeks treatment of once daily regiment of HCQ versus placebo as the reference group in patients with CLE and SLE with active skin manifestation (CLASI activity score is ≥4) concomitant treatment with or without corticosteroid. To investigate the safety of 16 weeks treatment of once daily regiment of HCQ in patients with CLE and SLE with active skin manifestation concomitant treatment with or without corticosteroid. To investigate the safety and efficacy of 52 weeks long-term treatment of once daily regimen of HCQ in patients with CLE and SLE - To investigate the influence of the dose reduction of corticosteroid on CLE and SLE patients treated with HCQ concomitant with corticosteroid To investigate efficacy of once daily regimen of HCQ on systemic symptoms, musculoskeletal symptoms and immunological parameters in SLE patients.
Detailed Description
Total 59 weeks (screening;4 weeks, treatment;52 weeks, Follow-up; 3 weeks)

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cutaneous Lupus Erythematosus-Systemic Lupus Erythematosus

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
103 (Actual)

8. Arms, Groups, and Interventions

Arm Title
HCQ
Arm Type
Active Comparator
Arm Description
HCQ 200~400mg, once daily, oral administration
Arm Title
Placebo
Arm Type
Other
Arm Description
HCQ-placebo, once daily, oral administration
Intervention Type
Drug
Intervention Name(s)
hydroxychloroquine (Z0188)
Other Intervention Name(s)
Plaquenil®
Intervention Description
Pharmaceutical form:tablet Route of administration: oral
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Pharmaceutical form:tablet Route of administration: oral
Primary Outcome Measure Information:
Title
A change in CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index) activity score
Time Frame
from baseline (at visit 2) to 16 weeks treatment (at visit 6)
Secondary Outcome Measure Information:
Title
A change in CLASI activity score
Time Frame
from baseline (at visit 2) to 52 weeks treatment (at visit 15)
Title
BILAG (British Isles Lupus Assessment Group) index to be conducted in patients complicated with SLE
Time Frame
7 timepoints during 52 weeks
Title
RAPID 3 (Routine assessment of patient index data 3) to be conducted in patients complicated with SLE : daily life activity, pain associated with the original disease, patient's severity related to the original disease
Time Frame
7 timepoints during 52 weeks
Title
QOL related to skin manifestations (skindex-29)
Time Frame
4 timepoints during 52 weeks
Title
Dose reduction of concomitant corticosteroid
Time Frame
From 16 weeks to 55 weeks after the initiation of the treatment
Title
Global assessment by investigator (skin and other)
Time Frame
3 timepoints during 52 weeks
Title
Global assessment by patient (skin)
Time Frame
3 timepoints during 52 weeks
Title
Immunological parameters
Time Frame
up to maximum of 13 timepoints during 52 weeks
Title
Number of patients with serious adverse events / adverse events
Time Frame
up to a maximum of 59 weeks
Title
Ophthalmologic examination (visual acuity examination, slit-lamp examination, funduscopic examination, visual field examination and color vision examination)
Time Frame
14 timepoints during 52 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion criteria : Patients diagnosed as cutaneous lupus erythematosus (CLE) Exclusion criteria: Patients receiving corticosteroid more than 15mg/day of the equivalent dose of prednisolone. Patients whose CLASI activity scores were less than 4 point at the initiation of Screening (Visit 1) and Day1 (Visit 2) (evaluated by a dermatology specialist). Patients whose fluctuations of CLASI activity scores were ≥20% between Visit 1 and Visit 2 (evaluated by a dermatology specialist). The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Clinical Sciences & Operations
Organizational Affiliation
Sanofi
Official's Role
Study Director
Facility Information:
Facility Name
Investigational Site Number 392017
City
Bunkyo-Ku
Country
Japan
Facility Name
Investigational Site Number 392022
City
Bunkyo-Ku
Country
Japan
Facility Name
Investigational Site Number 392011
City
Chuo-Ku, Kumamoto-Shi
Country
Japan
Facility Name
Investigational Site Number 392003
City
Chuo-Ku
Country
Japan
Facility Name
Investigational Site Number 392001
City
Fuchu-Shi
Country
Japan
Facility Name
Investigational Site Number 392008
City
Iruma-Gun
Country
Japan
Facility Name
Investigational Site Number 392009
City
Iruma-Gun
Country
Japan
Facility Name
Investigational Site Number 392005
City
Itabashi-Ku
Country
Japan
Facility Name
Investigational Site Number 392014
City
Kamogawa City
Country
Japan
Facility Name
Investigational Site Number 392019
City
Kanazawa-Shi
Country
Japan
Facility Name
Investigational Site Number 392007
City
Kitakyushu
Country
Japan
Facility Name
Investigational Site Number 392020
City
Maebashi-Shi
Country
Japan
Facility Name
Investigational Site Number 392012
City
Nagasaki-Shi
Country
Japan
Facility Name
Investigational Site Number 392010
City
Nagoya-Shi
Country
Japan
Facility Name
Investigational Site Number 392013
City
Nakagami-Gun
Country
Japan
Facility Name
Investigational Site Number 392006
City
Sagamihara-Shi
Country
Japan
Facility Name
Investigational Site Number 392018
City
Sagamihara-Shi
Country
Japan
Facility Name
Investigational Site Number 392002
City
Shinjuku-Ku
Country
Japan
Facility Name
Investigational Site Number 392023
City
Tomigusuku-Shi
Country
Japan
Facility Name
Investigational Site Number 392021
City
Uruma-Shi
Country
Japan
Facility Name
Investigational Site Number 392004
City
Wakayama-Shi
Country
Japan
Facility Name
Investigational Site Number 392016
City
Yokohama-Shi
Country
Japan

12. IPD Sharing Statement

Citations:
PubMed Identifier
33687069
Citation
Hannon CW, McCourt C, Lima HC, Chen S, Bennett C. Interventions for cutaneous disease in systemic lupus erythematosus. Cochrane Database Syst Rev. 2021 Mar 9;3(3):CD007478. doi: 10.1002/14651858.CD007478.pub2.
Results Reference
derived
PubMed Identifier
27992698
Citation
Yokogawa N, Eto H, Tanikawa A, Ikeda T, Yamamoto K, Takahashi T, Mizukami H, Sato T, Yokota N, Furukawa F. Effects of Hydroxychloroquine in Patients With Cutaneous Lupus Erythematosus: A Multicenter, Double-Blind, Randomized, Parallel-Group Trial. Arthritis Rheumatol. 2017 Apr;69(4):791-799. doi: 10.1002/art.40018.
Results Reference
derived

Learn more about this trial

Multicenter Study Assessing the Efficacy & Safety of Hydroxychloroquine Sulfate in Patients With Systemic Lupus Erythematosus or Cutaneous Lupus Erythematosus With Active Lupus Erythematosus Specific Skin Lesion

We'll reach out to this number within 24 hrs